Effect of Desmopressin on Platelet Function in CKD Patients on Antiplatelet Drug

Phase 1

Completed

• Conditions: Bleeding; Tachycardia; Dyspnea
• Interventions: Drug: Desmopressin administration

• Registration Number: NCT01841515
• Lead Sponsor: University of Ulsan

Brief Summary

Prolonged Collagen/Epinephrine - closure time (CEPI-CT) indicates platelet dysfunction in CKD patients taking antiplatelet agent. The synthetic vasopressin derivative, Desmopressin (DDAVP) shortens the prolonged bleeding time and improves platelet dysfunction measured by in vitro closure time: CEPI-CT in uremic patients. Desmopressin also antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors, clopidogrel and aspirin. The investigators designed a prospective study to evaluate the effect of desmopressin on platelet function, as measured by in vitro collagen/epinephrine - closure time, in uremic patients who were taking antiplatelet drugs.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-08
• Primary Completion: 2013-04
• Study Completion: 2013-04
• Study First Submitted: 2013-04-23
• Study First Submitted QC: 2013-04-25
• Study First Posted: 2013-04-26
• Status Verified: 2013-05
• Last Update Submitted: 2013-05-09
• Last Update Posted: 2013-05-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

• adult uremic patients with one or more antiplatelet medication,
• prolonged collagen/epinephrine (CEPI) closure time,
• need for emergent hemodialysis and
• subsequent catheter insertion

Exclusion Criteria

• acute coronary syndrome,
• hemophilia, and nephrogenic diabetes insipidus,
• allergy against desmopressin

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Desmopressin	Desmopressin administration	Twenty five patients with chronic kidney disease and who were taking antiplatelet agents and needed an emergent catheter insertion for hemodialysis

Primary Outcome Measures

Name	Time	Method
collagen-epinephrine closure time	1 hour	In vitro closure time (CT), measured using a platelet function analyzer (PFA)-100, is a relatively new tool for investigation of primary hemostasis. This system has been shown to be efficacious in evaluating abnormalities of primary hemostasis.

Secondary Outcome Measures

Name	Time	Method
Bleeding after procedure	1-4 hr after procedure	we observe incidence of bleeding complication after procedure

Trial Locations

Locations (1)

Asan Medical Center; 🇰🇷 Seoul, Songpa-gu, Korea, Republic of